Nightingale J A, Rogers D F, Hart L A, Kharitonov S A, Chung K F, Barnes P J
Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College School of Medicine, London, UK.
Thorax. 1998 Jul;53(7):563-71. doi: 10.1136/thx.53.7.563.
Inhalation of lipopolysaccharide (LPS) causes an inflammatory response in the lungs. To explore this response, inflammatory indices were measured in induced sputum from atopic asthmatic patients and compared with atopic and non-atopic subjects after inhalation of LPS.
The effects of inhaled LPS (60 micrograms) or placebo (0.9% saline) were examined in a randomised, double blind, crossover trial in 11 non-atopic normal subjects, seven atopic, non-asthmatic individuals, and eight atopic, asthmatic patients. Sputum was induced by inhalation of 3.5% saline before the test inhalation and again at six hours and 24 hours. Spirometry (forced expiratory volume in one second (FEV1), forced vital capacity (FVC)), heart rate, blood pressure, and temperature were recorded before challenge and at intervals until eight hours, and at 24 hours after challenge.
There was no change in cardiovascular parameters or spirometry with either exposure in any group. In the asthmatic patients only, inhalation of LPS caused a rise in temperature, with a peak of 0.6 degree C at seven hours, which was significantly higher than following placebo inhalation (p < 0.05). In normal subjects, LPS caused a significant rise in absolute neutrophil counts at 24 hours compared with placebo (median 1.1 x 10(6) cells/ml after LPS; median 0.2 x 10(6) cells/ml after placebo, p < 0.01), but no change in differential counts. In asthmatic patients, LPS caused a significant rise in differential neutrophil counts at six hours compared with placebo (median 88% after LPS; median 56% after placebo, p < 0.05), but no change in absolute cell counts at any time point. There was no change in neutrophil counts in the atopic subjects. There was a significant rise in sputum interleukin 8 (IL-8) concentrations in normal subjects at six hours compared with placebo (mean placebo 1.1 ng/ml; LPS 3.0 ng/ml, p < 0.05) and in asthmatics at 24 hours (mean placebo 2.0 ng/ml, LPS 6.9 ng/ml, p < 0.05). There were no changes in sputum concentrations of tumour necrosis factor alpha or granulocyte macrophage colony stimulating factor at any time.
Inhalation of LPS causes a neutrophilic inflammation with increases in IL-8 in both normal and asthmatic subjects.
吸入脂多糖(LPS)可引起肺部炎症反应。为探究这种反应,对特应性哮喘患者诱导痰中的炎症指标进行了测量,并与吸入LPS后的特应性和非特应性受试者进行了比较。
在11名非特应性正常受试者、7名特应性非哮喘个体和8名特应性哮喘患者中进行了一项随机、双盲、交叉试验,以检测吸入LPS(60微克)或安慰剂(0.9%盐水)的效果。在试验吸入前、吸入后6小时和24小时,通过吸入3.5%盐水诱导痰液。在激发前、直至8小时的间隔时间以及激发后24小时记录肺活量测定(一秒用力呼气量(FEV1)、用力肺活量(FVC))、心率、血压和体温。
任何一组在两种暴露情况下心血管参数或肺活量测定均无变化。仅在哮喘患者中,吸入LPS导致体温升高,在7小时时达到峰值0.6℃,显著高于吸入安慰剂后(p<0.05)。在正常受试者中,与安慰剂相比,LPS在24小时时导致绝对中性粒细胞计数显著升高(LPS后中位数为1.1×10⁶个细胞/毫升;安慰剂后中位数为0.2×10⁶个细胞/毫升,p<0.01),但分类计数无变化。在哮喘患者中,与安慰剂相比,LPS在6小时时导致中性粒细胞分类计数显著升高(LPS后中位数为88%;安慰剂后中位数为56%,p<0.05),但在任何时间点绝对细胞计数均无变化。特应性受试者的中性粒细胞计数无变化。与安慰剂相比,正常受试者在6小时时痰白细胞介素8(IL-8)浓度显著升高(安慰剂平均为1.1纳克/毫升;LPS为3.0纳克/毫升,p<0.05),哮喘患者在24小时时升高(安慰剂平均为2.0纳克/毫升,LPS为6.9纳克/毫升,p<0.05)。在任何时间,肿瘤坏死因子α或粒细胞巨噬细胞集落刺激因子的痰浓度均无变化。
吸入LPS在正常和哮喘受试者中均引起中性粒细胞炎症,同时IL-8增加。